You are here

BCG vaccination to reduce the impact of COVID-19 in healthcare workers (The BRACE trial)

Research project

*These pages are specifically for healthcare workers at BRACE trial sites.

What is BRACE?

Healthcare workers are at increased risk of contracting COVID-19, caused by SARS-CoV-2. 

The Bacille Calmette-Guérin (BCG) vaccine is designed to protect against tuberculosis (TB). However, it also boosts immunity to protect against other infections. The purpose of the BRACE trial is to find out whether BCG vaccination protects against COVID-19 or reduces severity of COVID-19 in healthcare workers.

Project Details

Healthcare workers are at greater risk of contracting COVID-19 disease. When healthcare workers are sick and unable to come to work, this puts extra pressure on the healthcare system.

The results of this trial will help us find out whether, in current and future novel viral outbreaks, BCG vaccination could be used as an early intervention to protect healthcare workers and other high-risk groups.

In the BRACE trial has recruited more than 6800 healthcare workers from Australia, Brazil, Spain, the Netherlands and the UK, who work in a healthcare setting or have face-to-face contact with patients. We do not tell the healthcare provider where you work which of their staff members have consented to participate in this trial. There are no costs associated with participating in this trial, nor will you be paid. All medication, tests and medical care required as part of the trial will be provided to you free of charge.

This project is a collaboration between our Campus Partners MCRI, Melbourne University and the Royal Children's Hospital.